Screener
NeoGenomics NEO Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 43.9%0.0pp | 43.2%-1.1pp | 43.2%-0.7pp | 43.5%-0.1pp | 43.9%+1.3pp | |
| Operating margin | -8.9%+7.8pp | -14.2%-1.0pp | -15.9%-2.0pp | -17%-2.7pp | -16.7%-1.5pp | |
| Net margin | -6.8%+8.3pp | -13.3%-1.8pp | -14.9%-2.9pp | -16%-3.9pp | -15.1%-2.6pp | |
| Returns | ||||||
| Return on equity | -6.3%+5.4pp | -11.6%-3.0pp | -12.4%-3.9pp | -13%-4.6pp | -11.8%-3.4pp | |
| Return on invested capital | -7.4%+9.1pp | -15.7%-1.6pp | -12.3%+0.2pp | -17.8%-3.9pp | -16.5%-2.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.5×+0.1× | 0.5×+0.1× | 0.5×+0.1× | 0.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 3.6×-0.3× | 4.4×+2.4× | 4.3×+2.3× | 3.9×+1.9× | 3.9×+1.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×+0.5× | 0.1×0.0× | 0.5×+0.2× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $6.01-10.0% | $6.42-8.0% | $6.53-8.3% | $6.53-8.7% | $6.67-7.9% | |
| Valuation | ||||||
| Market capitalization | $2B+182% | $963.21M-21.0% | $1.52B-28.1% | $997.26M-46.5% | $930.46M-46.8% | |
| Price / sales | 2.6×+1.6× | 1.3×-0.5× | 2.1×-1.1× | 1.4×-1.5× | 1.4×-1.4× | |
| Price / book | 2.5×+1.7× | 1.2×-0.2× | 1.8×-0.5× | 1.2×-0.9× | 1.1×-0.8× |
FAQ
- What are NeoGenomics's profit margins?
- NeoGenomics (NEO) runs a 43.9% gross margin and a -8.9% operating margin, with a -6.8% net margin.
- Where do NeoGenomics's ratios come from?
- Every ratio is computed from NeoGenomics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
